DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the third quarter of 2009 and for the nine-month period ended September 30, 2009. Neoprobe’s revenues for the third quarter of 2009 were $2.6 million compared to $1.7 million for the third quarter of 2008. Year-to-date revenues for the nine-month period ended September 30, 2009 were $7.1 million compared to $5.6 million for the same period of 2008. Neoprobe’s third quarter 2009 operating expenses were $2.0 million compared to $2.4 million for the third quarter of 2008. Operating expenses for the nine-month period ended September 30, 2009 were $6.1 million compared to $5.3 million for the same period of 2008. Neoprobe’s loss from operations for the third quarter of 2009 was $324,000 compared to $1.4 million for the third quarter of 2008. Neoprobe’s loss from operations for the nine-month period ended September 30, 2009 was $1.4 million compared to $1.8 million for the same period of 2008.
